and more
===========
Replenished the depleted Strategic National Stockpile.
Increased the number of ventilators nearly ten-fold to more than 153,000.
Despite the grim projections from the media and governors, no American who has needed a ventilator has been denied a ventilator.
Increased the number of N95 masks fourteen-fold to more than 176 million.
Issued an executive order ensuring critical medical supplies are produced in the United States.
Created the largest, most advanced, and most innovative testing system in the world.
Built the world’s leading testing system from scratch, conducting over 200 million tests – more than all of the European Union combined.
Engaged more than 400 test developers to increase testing capacity from less than 100 tests per day to more than 2 million tests per day.
Slashed red tape and approved Emergency Use Authorizations for more than 300 different tests, including 235 molecular tests, 63 antibody tests, and 11 antigen tests.
Delivered state-of-the-art testing devices and millions of tests to every certified nursing home in the country.
Announced more flexibility to Medicare Advantage and Part D plans to waive cost-sharing for tests.
Over 2,000 retail pharmacy stores, including CVS, Walmart, and Walgreens, are providing testing using new regulatory and reimbursement options.
Deployed tens of millions of tests to nursing homes, assisted living facilities, historically black colleges and universities (HBCUs), tribes, disaster relief operations, Home Health/Hospice organizations, and the Veterans Health Administration.
Began shipping 150 million BinaxNOW rapid tests to states, long-term care facilities, the IHS, HBCUs, and other key partners.
Pioneered groundbreaking treatments and therapies that reduced the mortality rate by 85 percent, saving over 2 million lives.
The United States has among the lowest case fatality rates in the entire world.
The Food and Drug Administration (FDA) launched the Coronavirus Treatment Acceleration Program to expedite the regulatory review process for therapeutics in clinical trials, accelerate the development and publication of industry guidance on developing treatments, and utilize regulatory flexibility to help facilitate the scaling-up of manufacturing capacity.
More than 370 therapies are in clinical trials and another 560 are in the planning stages.
Announced $450 million in available funds to support the manufacturing of Regeneron’s antibody cocktail.
Shipped tens of thousands of doses of the Regeneron drug.
Authorized an Emergency Use Authorization (EUA) for convalescent plasma.
Treated around 100,000 patients with convalescent plasma, which may reduce mortality by 50 percent.
Provided $48 million to fund the Mayo Clinic study that tested the efficacy of convalescent plasma for patients with COVID-19.
Made an agreement to support the large-scale manufacturing of AstraZeneca’s cocktail of two monoclonal antibodies.
Approved Remdesivir as the first COVID-19 treatment, which could reduce hospitalization time by nearly a third.
Secured more than 90 percent of the world’s supply of Remdesivir, enough to treat over 850,000 high-risk patients.
Granted an EUA to Eli Lilly for its anti-body treatments.
Finalized an agreement with Eli Lilly to purchase the first doses of the company’s investigational antibody therapeutic.
Provided up to $270 million to the American Red Cross and America’s Blood Centers to support the collection of up to 360,000 units of plasma.
Launched a nationwide campaign to ask patients who have recovered from COVID-19 to donate plasma.
Announced Phase 3 clinical trials for varying types of blood thinners to treat adults diagnosed with COVID-19.
Issued an EUA for the monoclonal antibody therapy bamlanivimab.
FDA issued an EUA for casirivimab and imdevimab to be administered together.
Launched the COVID-19 High Performance Computing Consortium with private sector and academic leaders unleashing America’s supercomputers to accelerate coronavirus research.
Market Data 
Markets 
AI
